Terms: = Prostate cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1
42026 results:
1. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract] [Full Text] [Related]
2. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
3. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.
Baudewyns A; Guenzel K; Halinski A; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Jabbour T; Bourgeno HA; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Zahr RA; Ploussard G; Fiard G; Rysankova K; Bui AP; Taha F; Windisch O; Benamran D; Vlahopoulos L; Assenmacher G; Roumeguère T; Peltier A; Diamand R
World J Urol; 2024 May; 42(1):322. PubMed ID: 38747982
[TBL] [Abstract] [Full Text] [Related]
4. Diabetes-related risk factors and survival among individuals with type 2 diabetes and breast, lung, colorectal, or prostate cancer.
Laurberg T; Witte DR; Gudbjörnsdottir S; Eliasson B; Bjerg L
Sci Rep; 2024 May; 14(1):10956. PubMed ID: 38740921
[TBL] [Abstract] [Full Text] [Related]
5. A bicentric retrospective study of the correlation of EAU BCR risk groups with
Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
[TBL] [Abstract] [Full Text] [Related]
6. Digital Adoption by an Organization Supporting Informal Caregivers During COVID-19 Pandemic Showing Impact on Service Use, Organizational Performance, and Carers' Well-Being: Retrospective Population-Based Database Study With Embedded User Survey.
Szczepura A; Khan AJ; Wild D; Nelson S; Woodhouse S; Collinson M
JMIR Aging; 2024 May; 7():e46414. PubMed ID: 38739915
[TBL] [Abstract] [Full Text] [Related]
7. Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on cancer Cell Lines.
Albani M; Fassi EMA; Moretti RM; Garofalo M; Montagnani Marelli M; Roda G; Sgrignani J; Cavalli A; Grazioso G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731842
[TBL] [Abstract] [Full Text] [Related]
8. A cross-sectional study of ERG expression and the relationship with clinicopathological features of prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract] [Full Text] [Related]
9. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
10. Risk of Subsequent Primary cancers Among Adult-Onset 5-Year cancer Survivors in South Korea: Retrospective Cohort Study.
Choi YY; Lee M; Kim EH; Lee JE; Jung I; Cheong JH
JMIR Public Health Surveill; 2024 May; 10():e48380. PubMed ID: 38717807
[TBL] [Abstract] [Full Text] [Related]
11. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract] [Full Text] [Related]
12. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in prostate cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract] [Full Text] [Related]
13. Identifying risk factors for hypoxemia during emergence from anesthesia in patients undergoing robot-assisted laparoscopic radical prostatectomy.
Zhang Q; Zhu L; Yuan S; Lu S; Zhang X
J Robot Surg; 2024 May; 18(1):200. PubMed ID: 38713381
[TBL] [Abstract] [Full Text] [Related]
14. [Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures].
Gromova OA; Filimonova MV; Torshin IY; Frolova DЕ
Ter Arkh; 2024 Apr; 96(3):266-272. PubMed ID: 38713042
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of a Cascaded Deep Learning-based Algorithm for prostate Lesion Detection at Biparametric MRI.
Lin Y; Yilmaz EC; Belue MJ; Harmon SA; Tetreault J; Phelps TE; Merriman KM; Hazen L; Garcia C; Yang D; Xu Z; Lay NS; Toubaji A; Merino MJ; Xu D; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
Radiology; 2024 May; 311(2):e230750. PubMed ID: 38713024
[TBL] [Abstract] [Full Text] [Related]
16. Impact of COVID-19 on the time to counseling and treatment of prostate cancer.
Filipas DK; Pose RM; Marks P; Tennstedt P; Beyer B; Tilki D; Isbarn H; Maurer T; Ludwig TA; Heinzer H; Steuber T
Aging Male; 2024 Dec; 27(1):2347465. PubMed ID: 38712892
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of quantitative whole body PET parameters on [
Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS
Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135
[TBL] [Abstract] [Full Text] [Related]
18. Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study.
Duwe G; Schmitteckert M; Haack M; Sparwasser P; Dotzauer R; Thomas A; Tsaur I; Brandt MP; Kurosch M; Mager R; Haferkamp A; Boehm K; Höfner T
World J Urol; 2024 May; 42(1):297. PubMed ID: 38709326
[TBL] [Abstract] [Full Text] [Related]
19. Establishment of primary prostate epithelial and tumorigenic cell lines using a non-viral immortalization approach.
Lange S; Kuntze A; Wüstmann N; Reckers T; Humberg V; Dirks WG; Huss S; Vieler J; Schrader AJ; Bögemann M; Schlack K; Bernemann C
Biol Res; 2024 May; 57(1):21. PubMed ID: 38704600
[TBL] [Abstract] [Full Text] [Related]
20. Effects of crotamine in human prostate cancer cell line.
Alberghini-Dos-Santos JV; Sanchez CA; Bordon KCF; Pucca MB; Antunes LMG; Arantes EC; Oliveira IS
Toxicon; 2024 May; 243():107746. PubMed ID: 38704124
[TBL] [Abstract] [Full Text] [Related]
[Next]